CLINICAL_TRIALS
trial_result
· 2023-07-18
Clinical Trial Update: Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis [Phase 1, Phase 2]
Summary
A study of intravenous Efzofitimod (ATYR1923) in pulmonary sarcoidosis has completed Phase 1 and Phase 2, with results posted in 2023.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: aTyr Pharma, Inc. | Conditions: Pulmonary Sarcoidosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-07-18